reneuron

ReNeuron’s stem cell therapy improves motor function in stroke study

pharmafile | December 5, 2016 | News story | Research and Development ReNeuron, stem cell, stem cell therapy, stroke 

ReNeuron, a UK-based biotechnology company, posted results of its experimental stem cell therapy for patients who had been disabled after a stroke. The study found that 15 out of 21 patients that were treated by the company’s CTX cell therapy showed statistical improvement on various scales during or after the course of the study.

Involving only 21 patients, the Phase 2 study was small in number but managed to display sufficient statistical efficacy to warrant attention. The company set the primary end point of the trial as 2 out of 21 patients experiencing improvement in motor function of one arm over a period of three months. The company failed to achieve this, with only one patient managing to meet this endpoint. However, with continued check up with patients, a further two were found to experience improvement at the six and 12 month point.

Beyond this, seven out of 21 were shown to have responded to treatment on the Modified Rankin Scale and a further eight responded when the Barthel Index was applied. The news was enough to boost shares in the company by 22%.

The treatment is administered by direct injection to the adjacent area of the brain that was damaged by the patients’ stroke. This involved 20 million CTX cells being introduced to the brain within two to thirteen months of the stroke.

Olav Hellebø, CEO of ReNeuron, said: “We are delighted that the PISCES II clinical trial has shown our CTX cell therapy candidate has the potential to become a treatment option for patients living with chronic consequences following stroke. We are particularly excited by the response rate seen on the measures relating to disability and activities of daily living, given that these are the most important for patients and their carers. These measures are also the ones viewed by regulatory authorities as most relevant for late-stage clinical development.”

Ben Hargreaves

Related Content

American Heart Association awards $2.1m to research link between migraine, strokes and CVD

The American Heart Association has announced that it will fund seven new scientific research studies …

milad-fakurian-58z17lnvs4u-unsplash_2

NHS given guidance on offering genetic testing to stroke patients

The NHS has been given draft guidance on offering gene tests to patients who have …

36745826313_86e4ffa6ac_b

New Johnson & Johnson study aiming to add stroke detection to Apple Watch

Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore …

Latest content